CNS Pharmaceuticals to present on TPI 287 at Brain Tumor Biotech Summit

CNS Pharmaceuticals (CNSP) announced that Sandra Silberman, Chief Medical Officer, will present at the Lenox Hill Hospital, Department of Neurosurgery’s Brain Tumor Biotech Summit being held on June 5, in New York, NY. Title: The Future and Promise of TPI 287- A Brain Penetrating Taxane with Documented Evidence of Efficacy Against Glioblastoma” As part of the presentation Dr. Silberman will discuss the Company’s drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier, TPI 287’s clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab, the efficacy data included 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients.